Inquiry Basket
Cys-MC-MMAF is the released payload of AlMcMMAF, an anti-5T4 humanized A1 antibody that is conjugated to microtubule MMAF destruction via a maleimidocaproyl linker. It has antitumor effects on two tumor mouse models (H1975 and MDA-MB-361-DYT2).
| Catalog Number | Size | Price | Quantity | ||
|---|---|---|---|---|---|
| BADC-01432 | -- | $-- | Inquiry |
Cys-MC-MMAF, a potent cytotoxic agent utilized in targeted cancer therapies, shines in the realm of antibody-drug conjugates (ADCs). Here are four key applications of Cys-MC-MMAF:
Cancer Treatment: Embedded within antibody-drug conjugates, Cys-MC-MMAF forms a lethal bond with an antibody that meticulously targets cancerous cells. Upon fusion with the targeted cell, the ADC undergoes internalization, freeing Cys-MC-MMAF to unleash its cytotoxic prowess within. This targeted strategy not only minimizes harm to healthy cells but also amplifies the effectiveness of cancer therapy by optimizing the destruction of malignant cells.
Research and Development of ADCs: A cornerstone in the realm of antibody-drug conjugate innovation, Cys-MC-MMAF serves as an indispensable tool for crafting and evaluating novel ADCs. Researchers harness its potency to probe diverse antibody conjugates, fine-tuning their therapeutic efficacy. Acting as a prototype compound, Cys-MC-MMAF facilitates the meticulous assessment of ADCs’ strength and selectivity in preliminary research studies, setting the stage for enhanced cancer treatment modalities.
In Vivo Tumor Models: Employed within animal models, Cys-MC-MMAF plays a pivotal role in deciphering the pharmacokinetic and pharmacodynamic dynamics of emerging ADCs. Through in-depth in vivo evaluations, researchers unravel the distribution, efficacy, and toxicology profiles of these conjugates, a critical step in transitioning ADCs from experimental stages to clinical trials. This investigative process lays the groundwork for advancing the efficacy and safety of future cancer treatments.
Mechanistic Studies: Delving into the intricate workings of ADCs, researchers rely on Cys-MC-MMAF to unravel the mechanisms underlying their actions and potential resistance factors. By scrutinizing how cancer cells interact with and process the drug, as well as anticipating the emergence of treatment resistance, scientists pave the way for designing sophisticated next-generation ADCs with heightened effectiveness in combating cancer.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
